Product Description: Niclosamide-d3 (BAY2353-d3) is deuterium labeled Niclosamide. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].
Applications: COVID-19-immunoregulation
Formula: C13H5D3Cl2N2O4
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95./[3]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96./[4]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66./[5]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9./[6]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.
CAS Number: 2665663-60-3
Molecular Weight: 330.14
Research Area: Infection;Cancer
Target: Antibiotic;Isotope-Labeled Compounds;Parasite;STAT
English
Deutsch
